Produce Phase II Clinical Data on 20 Indian Subjects to Determine Dose: CDSCO panel advises Pfizer on Ritlecitinib.

Published Date: 11 Sep 2023

New Delhi: It should be noted that the study disease is extremely heterogeneous and that no Indian subjects were included in the data from the Phase II clinical trial that was presented.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Remote monitoring can improve recovery from cancer surgery

2.

Intractable cancers may respond better to treatment when using new radiation and high-performance computing.

3.

A Win for AI in Cancer; 2025's Transformative Drugs; FDA Clarifies 'Underway' Trials

4.

Conditional EU Nod for Weekly Pill in Pediatric Glioma

5.

high response rate when using a bispecific antibody to treat R/R multiple myeloma.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot